Companies › Samsung Bioepis
4 active drug programs in 5 registered trials: 3 Phase 1, 1 Phase 3, 1 Phase 2; Oncology, Other, Ophthalmology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Pembrolizumab (SB27) Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Stage II | Nov 2026 |
| Aflibercept (SB15) Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor | VEGFA, PGF | Phase 2 | Neovascular Age-related Macular Degeneration | – |
| SB35 IL-17A receptor antagonist | IL17RA | Phase 1 | Healthy | Jun 2027 |
| E303 nectin-4 targeting antibody-drug conjugate | NECTIN4 | Phase 1 | Advanced Solid Tumors | Jul 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07844343 | Aflibercept (SB15) | Phase 2 | Neovascular Age-related Macular Degeneration | Ophthalmology | Sep 2026 |
| NCT06268613 | Pembrolizumab (SB27) | Phase 1 | Non-small Cell Lung Cancer Stage II | Oncology | Nov 2026 |
| NCT07789964 | SB35 | Phase 1 | Healthy | Other | Jun 2027 |
| NCT06348199 | Pembrolizumab (SB27) | Phase 3 | Non-small Cell Lung Cancer Stage IV | Oncology | Aug 2027 |
| NCT07524348 | E303 | Phase 1 | Advanced Solid Tumors | Oncology | Jul 2030 |
CStone Pharmaceuticals Shanghai Fudan-Zhangjiang Bio-Pharmaceutical TaiRx Alvotech Swiss RemeGen
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.